To include your compound in the COVID-19 Resource Center, submit it here.

Polaris’ Pandion partners with Astellas on diabetes bispecifics

By Elizabeth S. Eaton, Staff Writer | Oct 31, 2019 | 3:01 AM GMT

Formed by Polaris Partners to develop therapies that restore immune homeostasis at the site of disease, Pandion has entered its first large pharma partnership under which it will work with Astellas to discover

Read the full 331 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE